首页> 外文期刊>AIDS >Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma
【24h】

Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma

机译:与艾滋病相关的原发性中枢神经系统淋巴瘤患者的生存相关因素

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: AIDS-related primary central nervous system lymphoma (AR-PCNSL) has a poor prognosis. Improved understanding of specific patient, infectious, diagnostic, and treatment-related factors that affect overall survival (OS) is required to improve outcomes. Design: Population-based registry linkage study. Methods: Adult cases from the San Francisco AIDS registry (1990-2000) were matched with the California Cancer Registry (1985-2002) to ascertain AR-PCNSL data. Survival time was assessed through 31 December 2007. Risk factors and temporal trends for death were measured using two-sided Kaplan-Meier and Cox analyses. Results: Two hundred and seven AR-PCNSL patients were identified: 68% were white, 20% Hispanic, 10% African-American, and 2% Asian. Nineteen percent of patients had central nervous system (CNS) opportunistic infections diagnosed prior to ARPCNSL. Fifty-seven percent of patients received radiation and/or chemotherapy and 12% used HAART prior to or within 30 days of AR-PCNSL diagnosis. One hundred and ninety-nine patients died (34 deaths/100 person-years). In adjusted analysis, prior CNS opportunistic infection diagnosis increased risk of death (hazard ratio 1.9, P=0.0006) whereas radiation and/or chemotherapy decreased risk (hazard ratio 0.6, P<0.0001). AR-PCNSL diagnosis 1999-2002 had a lower mortality risk (hazard ratio=0.4, P=0.02) compared to 1990-1995. African-Americans had an increased risk of death compared to whites or Asians (hazard ratio=2.0, P=0.007). Conclusion: OS among AR-PCNSL patients improved over time but remains poor, especially among African-Americans. Prospective evaluation of curative therapy in AR-PCNSL is urgently needed. Accurate diagnosis of CNS mass lesions in patients with AIDS is required and for those with AR-PCNSL, antiretroviral therapy with concomitant AR-PCNSL therapy, and antimicrobial supportive care may improve OS.
机译:目的:与艾滋病有关的原发性中枢神经系统淋巴瘤(AR-PCNSL)预后较差。需要改善对影响总生存期(OS)的特定患者,感染,诊断和治疗相关因素的了解,以改善治疗效果。设计:基于人口的注册表链接研究。方法:将来自旧金山艾滋病登记处(1990-2000年)的成年病例与加利福尼亚癌症登记处(1985-2002年)相匹配,以确定AR-PCNSL数据。评估生存期至2007年12月31日。使用双面Kaplan-Meier和Cox分析法测量死亡的危险因素和时间趋势。结果:鉴定出207例AR-PCNSL患者:白人占68%,西班牙裔占20%,非裔美国人占10%,亚裔占2%。 19%的患者在ARPCNSL之前被诊断出患有中枢神经系统(CNS)机会性感染。 57%的患者在AR-PCNSL诊断之前或30天内接受了放疗和/或化疗,12%的患者使用了HAART。一百九十九名患者死亡(34死亡/ 100人年)。在调整后的分析中,先前的中枢神经系统机会感染诊断增加了死亡风险(危险比1.9,P = 0.0006),而放疗和/或化疗降低了危险(危险比0.6,P <0.0001)。与1990-1995年相比,AR-PCNSL诊断1999-2002年的死亡率较低(危险比= 0.4,P = 0.02)。与白人或亚洲人相比,非洲裔美国人的死亡风险增加(危险比= 2.0,P = 0.007)。结论:AR-PCNSL患者的OS随时间改善,但仍然较差,尤其是在非裔美国人中。迫切需要对AR-PCNSL中的治疗方法进行前瞻性评估。 AIDS患者中枢神经系统大块病变的准确诊断是必需的,对于AR-PCNSL患者,抗逆转录病毒疗法与AR-PCNSL疗法并用抗菌支持治疗可能会改善OS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号